Surrozen Inc SRZN Q1 2026 Earnings Significant EPS Miss Reflects Ongoing ClinicalStage Spending No Revenue Reported Tempest Therapeutics Inc TPST Q1 2026 Earnings Significant EPS Miss with No Revenue Stock Edges Up TFIN Q1 2026 Earnings EPS Surpasses Estimates by 569 on Strong Core Operations AIXC Q3 2023 Earnings Significant EPS Beat Despite Net Loss HESM Q1 2026 Earnings EPS Beat of 325 Drives Modest Stock Gain IFS Q1 2026 Earnings EPS Surpasses Estimates by Nearly 11